VYNE Therapeutics Inc. Revenue From Contract With Customer Excluding Assessed Tax

• VYNE Therapeutics Inc. showed an increase of +13.8% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
• This data is from VYNE Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on February 27, 2026.
• XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 8 years of available data (2018 to 2025), VYNE Therapeutics Inc.'s Revenue From Contract With Customer Excluding Assessed Tax has declined by 84.1%.
• Historical annual values: Fiscal year 2025: $570.0 thousand | Fiscal year 2024: $501.0 thousand | Fiscal year 2023: $424.0 thousand | Fiscal year 2022: $477.0 thousand | Fiscal year 2021: $931.0 thousand | Fiscal year 2020: $20.99 million | Fiscal year 2019: $443.0 thousand | Fiscal year 2018: $3.60 million.
• Data sourced from SEC EDGAR public filings as of June 23, 2026.

Last verified: June 23, 2026